OpportunityTitle: Targeted Capacity Expansion:  Medication Assisted Treatment - Prescription Drug and Opioid Addiction (Short Title: MAT-PDOA)
AdditionalInformationOnEligibility: As the 2017 Omnibus requires, eligibility is limited to the states with the highest rates of admissions, including those that have demonstrated a dramatic increase in admissions for the treatment of opioid use disorder. See Appendix E for a list of eligible states.  The application must be submitted by the Single State Agency (SSA) for Substance Abuse within the state.  FY 2015 MAT-PDOA grantees funded under announcement TI-15-007 and FY 2016 MAT-PDOA grantees funded under announcement TI-16-014 are not eligible to apply for this program.
Description: The Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), is accepting applications for fiscal year (FY) 2017 Targeted Capacity Expansion: Medication Assisted Treatment - Prescription Drug and Opioid Addiction (MAT-PDOA) grants. The purpose of this program is to expand/enhance access to medication-assisted treatment (MAT) services for persons with an opioid use disorder seeking or receiving MAT. This program targets states identified with having the highest rates of primary treatment admissions for heroin and opioids per capita and includes those with the most dramatic increases for heroin and opioids, as identified by SAMHSA&#8217;s Treatment Episode Data Set (TEDS): 2007 &#8211; 2014. The desired outcomes include: 1) an increase in the number of admissions for MAT; 2) an increase in the number of clients receiving integrated care/treatment; 3) a decrease in illicit opioid drug use at six-month follow-up; and 4) a decrease in the use of prescription opioids in a non-prescribed manner at six-month follow-up. For the purpose of this FOA, integrated care/treatment is defined as the organized delivery and/or coordination of medical (including the use of Food and Drug Administration (FDA)-approved drugs [buprenorphine, methadone, extended release injectable naltrexone] for addiction), behavioral, social, peer, and other recovery support services provided to individual patients who have multiple healthcare needs in order to produce better overall health outcomes. MAT is defined as the use of FDA-approved opioid agonist medications (e.g., methadone, buprenorphine products, including buprenorphine/naloxone combination formulations and buprenorphine mono-product formulations) for the maintenance treatment of opioid use disorder and opioid antagonist medication (e.g., extended-release) in combination with behavioral therapies to prevent relapse to opioid use. MAT includes screening, assessment (which includes determination of severity of opioid use disorder, including presence of physical dependence and appropriateness for MAT), and case management. MAT is to be provided in combination with comprehensive opioid use disorder treatment, including but not limited to: counseling, behavioral therapies, other clinically appropriate services in order for individuals to achieve and maintain abstinence from all opioids and heroin, and, when needed, pharmacotherapy for co-occurring alcohol use disorder. MAT is to be provided in a clinically driven, person-centered, and individualized setting.
GrantorContactEmailDescription: FOACSAT@samhsa.hhs.gov
GrantorContactText: Eileen Bermudez &lt;br/&gt;Office of Financial Resources, Division of Grants Management &lt;br/&gt;Substance Abuse and Mental Health Services Administration  &lt;br/&gt;(240) 276-1412